ADMA Biologics: Sell-Off Provides Buying Opportunity Ahead Of Projected Growth

Photo by Pixelimage/E+ via Getty Images
ADMA Biologics (ADMA) recently reported their Q4/2020 earnings with a slight miss on EPS and a slight beat on revenue. Despite the record revenue and strengthened balance sheet, the market punished ADMA in the subsequent trading days and is now trading just above its 52-week low. I believe this recent sell-off is unjustified and could be a great opportunity to buy ADMA at a deep discount.
I intend to review ADMA’s Q4/2020 earnings and will highlight some…

Click here to view the original article.